Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Downstaging of Hepatocellular Carcinoma with Macrovascular Invasion by Radiotherapy (SBRT or Y90) and Atezolizumab Plus Bevacizumab Followed by Liver Transplantation - a Prospective Trial

NCT06725121 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT06725121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06725121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Downstaging of Hepatocellular Carcinoma with Macrovascular Invasion by Radiotherapy (SBRT or Y90) and Atezolizumab Plus Bevacizumab Followed by Liver Transplantation - a Prospective Trial
Lead sponsor
University Health Network, Toronto
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 31, 2024
Completion date
June 30, 2034
Enrollment
48 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

downstaging, hepatocellular carcinoma (hcc), liver transplant surgery, macrovascular invasion